[HTML][HTML] Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer …
A Inoue, K Kobayashi, M Maemondo, S Sugawara… - Annals of oncology, 2013 - Elsevier
Background NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with …
A Inoue, K Kobayashi, M Maemondo… - Annals of Oncology …, 2012 - europepmc.org
Background NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …
[引用][C] Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin―paclitaxel for chemo-naïve non-small cell lung cancer …
A INOUE, K KOBAYASHI, Y FUJITA… - Annals of …, 2013 - pascal-francis.inist.fr
Author INOUE, A 1; KOBAYASHI, K 2; FUJITA, Y 11; OKINAGA, S 12; HIRANO, H 13;
YOSHIMORI, K 14; HARADA, T 15; SAIJO, Y 16; HAGIWARA, K 17; MORITA, S 18; NUKIWA …
YOSHIMORI, K 14; HARADA, T 15; SAIJO, Y 16; HAGIWARA, K 17; MORITA, S 18; NUKIWA …
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with …
A Inoue, K Kobayashi, M Maemondo… - Annals of …, 2013 - tohoku.elsevierpure.com
Background: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …
[PDF][PDF] Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with …
A Inoue, K Kobayashi, M Maemondo… - Annals of …, 2013 - researchgate.net
Background: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …
[PDF][PDF] Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with …
A Inoue, K Kobayashi, M Maemondo… - Annals of …, 2013 - med.niigata-u.ac.jp
Background: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with …
A Inoue, K Kobayashi, M Maemondo… - Annals of oncology …, 2013 - pubmed.ncbi.nlm.nih.gov
Background NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with …
A Inoue, K Kobayashi, M Maemondo… - Annals of …, 2013 - annalsofoncology.org
Background NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …
[引用][C] Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with …
A Inoue, K Kobayashi, M Maemondo, S Sugawara… - Annals of …, 2013 - cir.nii.ac.jp
Updated overall survival results from a randomized phase III trial comparing gefitinib with
carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene …
carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene …
Updated Overall Survival Results from A Randomized Phase III Trial Comparing Gefitinib with Carboplatin-Paclitaxel for Chemo-Naïve Non-Small Cell Lung Cancer …
A Inoue - annalsofoncology.org
BACKGROUND NEJ002, comparing gefitinib with carboplatin plus paclitaxel (CBDCA/PTX)
as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an …
as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an …